Manual lab quality control is the most underestimated productivity constraint in digital pathology. Every slide triggering a manual QC check, a rescanning decision, or a refocus intervention is a workflow interruption that costs staff time, creates process variability, and accumulates into a compounding throughput problem at scale.

There is a specific operational frustration that every lab manager who has run a digital pathology workflow recognizes: the scanner is not the bottleneck. The QC is. A scanner's rated throughput assumes that every slide scans cleanly on the first pass, no rescans , no manual review, no exception handling. In practice, a meaningful share of slides trigger at least one of those interventions, and each one is a workflow interruption that the specification sheet doesn't account for. The effective throughput is not what the specification sheet says. It is what the workflow, including all of its manual intervention points, actually delivers.

This is a lab automation problem that the most operationally mature digital pathology deployments are now solving, and the problem that underpins most of the productivity gap between what labs expected from digital pathology and what they are experiencing. Understanding this problem, and how modern automation platforms address it, may be the most valuable technical insight a lab manager can gain before evaluating their next scanner.

The Lab QC Problem: Why Manual Inspection Is a Structural Bottleneck

Quality control in a digital pathology workflow is not optional. An out-of-focus image that reaches a pathologist without correction is a patient safety event. A slide with a tissue fragment outside the scan area signed out without detection is a clinical error. Manual QC, where an operator visually inspects scanned images, identifies issues, and triggers rescans, has been the dominant approach in first- and second generation digital pathology deployments. It is also the dominant source of non-scanning workflow overhead in those same deployments.

The Schwen et al. (2023) comprehensive review of digitization lessons learned documented QC overhead quantitatively: one published implementation estimated 1 FTE per 3–4 WSI scanners specifically for image QC functions. At a laboratory operating five scanners, that is 1.25–1.67 FTE whose primary function is watching scanned images for quality issues that an automated system could detect and act on without human involvement.

The Impact of Pathology Lab Automation on Workflow Accuracy

The QC overhead compounds with volume. At 500 slides per day with a 5% rescan rate, 25 slides per day require manual handling outside the normal scan workflow. Over a 250-day working year, that is 6,250 interruptions - each a staff intervention that consumes time, introduces process variability, and extends the cycle time for the affected case. The cumulative throughput cost of a 5% rescan rate is not 5% of throughput. It is 5% of throughput plus all the time spent on the manual intervention cycle per rescan event.

Four Automation Tiers: What ‘Automated QC’ Actually Means

Not all automated QC is equivalent. The term covers a spectrum from basic flagging to fully autonomous corrective action. The operational significance of each tier is materially different for lab managers planning staffing and throughput.

Most first-generation digital pathology deployments operate at Tier 1 or Tier 2: the system detects quality issues but relies on staff to review exceptions and decide whether and how to rescan. This is operationally better than no QC automation, but it does not remove staff dependency from the quality assurance process. A Tier 1 system does not reduce the number of quality exceptions requiring staff review, instead it only organizes them into a queue. At the rescan volumes typical of high-throughput operation, that queue can represent a substantial share of a shift's available staff time. The operator is still the bottleneck; the system has organized the queue.

Tier 3 automation is the operational threshold at which automated QC becomes a genuine throughput enabler rather than a workflow management tool. At this level, software detects quality issues and initiates corrective action without staff involvement. This is where the FTE productivity case becomes unambiguous: the staff member is not removed from the workflow because their function was unimportant. They are freed from a repetitive monitoring and decision function that a properly designed system can perform without human involvement.

Sample Detection: The Automation Step Before QC 

Before a scanner can assess image quality, it must locate the tissue. In a manual or semi-automated workflow, an operator or basic macro camera system identifies the tissue area, and the scan covers that area, which may or may not correspond precisely to the diagnostically relevant tissue. Under- or over-scanning wastes scanner time and creates images that either miss tissue or contain excessive background.

Algorithm-based sample detection addresses this pre-scan step. Rather than relying on a generic macro camera image to estimate tissue location, an AI-based algorithm identifies the precise location and boundaries of tissue on the slide before scanning begins. This has two direct operational consequences: the scan area is optimized to the actual tissue extent, reducing unnecessary scan time per slide; and the resulting image contains the tissue in the expected spatial relationship to the scan frame, reducing the rate of post-scan quality failures caused by tissue position variability (US FDA, 2025).

AI in Pathology: Accelerating Digital Workflow Performance

The scan time impact of sample detection optimization is quantified in the literature. One published implementation reported that scan time per slide dropped from a median of 98 seconds to 74 seconds after optimizing fragment placement and scanner parameters. The result was a 24% reduction in effective scan time per slide (Schwen et al., 2023). Algorithm-based sample detection produces an equivalent improvement automatically, without requiring manual optimization by an operator who understands scanner parameters. 

What These Automation Features Look Like in 2026-Generation Systems 

The Epredia E1000 Dx Digital Pathology Solution, which received FDA 510(k) clearance in February 2025, represents the current generation of automation integration in a clinically cleared WSI system. Understanding what is specifically automated - and what remains manual - in this platform gives a useful reference point for evaluating any digital pathology scanner’s automation claims. 

The FTE Calculation: What Lab Automation Is Worth in Staff Hours 

For a lab manager building a business case for digital pathology automation, the FTE savings from QC automation can be estimated from published operational data.

QC staffing benchmarks: one FTE per 3–4 scanners for image QC (Schwen et al., 2023). Tier 3 automated QC reduces this requirement substantially. The time previously spent reviewing and deciding on focus-related 4 of 6 issues is absorbed by the automated system, leaving staff to handle genuinely complex QC exceptions that require human judgement.

Rescan time: at 5% rescan rate with 500 slides per day, manual rescan management consumes approximately 25 staff interventions per day. At 5 minutes per intervention, that is 125 staff-minutes per day, or roughly 0.25 FTE. Automated Tier 3 rescan eliminates this entirely for focus-related quality failures, which represent the majority of rescan events in practice.

Scan optimization: Sample detection produces approximately the same per-slide time saving as manual scan parameter optimization, without requiring a trained operator to perform or supervise it. At 500 slides per day and 24 seconds saved per slide, that is 200 minutes of scanner time recovered per day - equivalent to approximately 100 additional slides within the same shift window.

Improving Lab Efficiency & Productivity at Scale 

Conclusion: Lab Automation Is the Foundation, Not the Feature List 

Lab managers evaluating digital pathology are operating in a fundamentally different automation landscape than those who evaluated first-generation systems a decade ago. The question is no longer whether digital pathology reduces manual overhead. It does, and the evidence base is extensive. The question is how much of that overhead reduction depends on sophisticated staff to operate the QC process versus how much is autonomous.

For a lab manager whose operational constraint is not scanner hardware but staff availability and process consistency, the answer to that question determines how much of the promised efficiency is achievable in their specific environment. Automation that still requires experienced staff to identify and act on quality exceptions is operationally better than no automation. Automation that identifies and acts without those staff is operationally transformational. That is the distinction between scanner generations. It is also the distinction that matters most for a lab manager planning a digital pathology operation in 2026.

Digital Pathology Lab Automation: Key Takeaways for Lab Managers

References

1. Schwen, L. O., Kiehl, T. R., Carvalho, R., Zerbe, N., & Homeyer, A. (2023). Digitization of pathology labs: A review of lessons learned. Laboratory Investigation, 103(11), 100244. Read more.
2. Ardon, O., Klein, E., Manzo, A., Corsale, L., England, C., Mazzella, A., Geneslaw, L., Philip, J., Ntiamoah, P., Wright, J., Sirintrapun, S. J., Lin, O., Elenitoba-Johnson, K., Reuter, V. E., Hameed, M. R., & Hanna, M. G. (2023). Digital pathology operations at a tertiary cancer center: Infrastructure requirements and operational cost. Journal of Pathology Informatics, 14, 100318. Read more. 
3. US Food and Drug Administration. (2025). 510(k) premarket notification K241717: Epredia E1000 Dx Digital Pathology Solution. FDA CDRH. Read more.
4. Hanna, M. G., Reuter, V. E., Samboy, J., England, C., Corsale, L., Fine, S. W., Klimstra, D. S., & Travis, W. D. (2020).
   Implementation of digital pathology offers clinical and operational increase in efficiency and cost savings. Archives of
   Pathology & Laboratory Medicine, 143(12), 1545–1555. Read more.
5. Kuhlman, B., & Bedi, R. (2025). Comparative analysis of FDA-cleared whole slide imaging systems for primary
   diagnosis. International Journal of Pathology and Clinical Research, 11(1), 165. Read more.
6. Munari, E., Zamboni, G., Cecchini, M. J., Zamo, A., Sommaggio, M., & Brunelli, M. (2024). Pathology in motion:
   Automation from specimen to report. Annals of Diagnostic Pathology. Read more.
7. Walsh, E., & Orsi, N. (2024). The current troubled state of the global pathology workforce: A concise review. Diagnostic
   Pathology, 19, 63. Read more.
8. Vodovnik, A. (2024). Non-diagnostic time in digital pathology: An empirical study over 10 years. Journal of Pathology
   Informatics, 15, 100393. Read more.
9. Bruce, A., Goodsell, J., Sayers, T., Allen, S., Hooper, A., Murphy, D., & Sheridan, C. (2024). Transforming diagnostics:
   The implementation of digital pathology in clinical laboratories. Histopathology, 85(1), 4–13. Read more.